{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:49:19Z","timestamp":1773316159796,"version":"3.50.1"},"reference-count":29,"publisher":"BMJ","issue":"e3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2022,10,19]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To describe the contemporary real-world use of cyclizine for nausea or vomiting, and the associated benefits and harms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a prospective, consecutive case series of routine clinical use of cyclizine for nausea or vomiting in palliative care conducted across 19 sites in Australia, Aotearoa\/New Zealand and the UK. Clinical outcomes were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events at baseline and 72 hours after initiation of cyclizine. Ad hoc safety reporting continued for 2 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data were collected from 101 patients between May 2018 and December 2020. Cyclizine was mostly used in combination with another antiemetic. Overall, 79 patients benefited and 32 experienced harm (56 had benefit without harm; 9 had harm without benefit). The most common harms were constipation (13%), somnolence (9%) and confusion (7%), adding to the already high rates of these symptoms at baseline. For the four patients with serious harms (grade \u22653), these were exacerbations of existing symptoms. Nine patients stopped cyclizine at 72 hours and a further 20 patients within 2 weeks. The most common reasons for stopping were lack of benefit and symptom resolution; none stopped because of harms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>When used as described in a palliative care setting, cyclizine benefits about three-quarters of patients, with about one-third experiencing tolerable harms.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2022-003795","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T18:20:16Z","timestamp":1668104416000},"page":"e1191-e1197","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Cyclizine pharmacovigilance in hospice\/palliative care: net effects for nausea or vomiting"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9876-9368","authenticated-orcid":false,"given":"Richard","family":"McNeill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Prael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungwon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wilcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dunwoodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salina","family":"Iupati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C","family":"Currow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"2024051713081435000_13.e3.e1191.1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jpainsymman.2011.04.022","article-title":"The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients","volume":"43","author":"Vella-Brincat","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"2024051713081435000_13.e3.e1191.2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.4155\/tde-2016-0023","article-title":"Bioequivalence study of cyclizine hydrochloride 50 Mg tablets in healthy volunteers: a randomized, open-label, single-dose study","volume":"7","author":"Abhyankar","year":"2016","journal-title":"Ther Deliv"},{"key":"2024051713081435000_13.e3.e1191.3","unstructured":"Walker RB . Hplc analysis and pharmacokinetics of cyclizine. Rhodes University, 1995."},{"key":"2024051713081435000_13.e3.e1191.4","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198510060-00002"},{"key":"2024051713081435000_13.e3.e1191.5","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeg120"},{"key":"2024051713081435000_13.e3.e1191.6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF03170501","article-title":"Cyclizine and droperidol have comparable efficacy and side effects during patient-controlled analgesia","volume":"171","author":"Laffey","year":"2002","journal-title":"Ir J Med Sci"},{"key":"2024051713081435000_13.e3.e1191.7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2125.1975.tb00476.x","article-title":"A comparison of the efficacy of cyclizine and perhenazine in reducing the emetic effects of morphine and pethidine","volume":"2","author":"Dundee","year":"1975","journal-title":"Br J Clin Pharmacol"},{"key":"2024051713081435000_13.e3.e1191.8","doi-asserted-by":"publisher","DOI":"10.2165\/0003495-200868180-00004"},{"key":"2024051713081435000_13.e3.e1191.9","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-020-00813-0","article-title":"The management of nausea and vomiting not related to anticancer therapy in patients with cancer","volume":"22","author":"Hardy","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"2024051713081435000_13.e3.e1191.10","first-page":"261","article-title":"What are the essential medications in pallative care? - a survey of Australian palliative care doctors","volume":"35","author":"Good","year":"2006","journal-title":"Aust Fam Physician"},{"key":"2024051713081435000_13.e3.e1191.11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1089\/jpm.2012.9605","article-title":"An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice","volume":"15","author":"Currow","year":"2012","journal-title":"J Palliat Med"},{"key":"2024051713081435000_13.e3.e1191.12","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1089\/jpm.2012.0111","article-title":"Pharmacovigilance in hospice\/palliative care: rapid report of net clinical effect of metoclopramide","volume":"15","author":"Currow","year":"2012","journal-title":"J Palliat Med"},{"key":"2024051713081435000_13.e3.e1191.13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/jpm.2017.0159","article-title":"Pharmacovigilance in Hospice\/Palliative care: net effect of haloperidol for nausea or vomiting","volume":"21","author":"Digges","year":"2018","journal-title":"J Palliat Med"},{"key":"2024051713081435000_13.e3.e1191.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2024051713081435000_13.e3.e1191.15","unstructured":"Anon . National cancer Institute common terminology criteria for adverse events (CTCAE), version 5.0. Bethesda, MD National Cancer Institute, National Institutes of Health; 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf [Accessed 25 Nov 2021]."},{"key":"2024051713081435000_13.e3.e1191.16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"2024051713081435000_13.e3.e1191.17","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1089\/jpm.2013.0610","article-title":"Prescribing for nausea in palliative care: a cross-sectional national survey of Australian palliative medicine doctors","volume":"17","author":"To","year":"2014","journal-title":"J Palliat Med"},{"key":"2024051713081435000_13.e3.e1191.18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jpainsymman.2004.02.004","article-title":"Chlorpheniramine maleate as an alternative to antiemetic cyclizine","volume":"27","author":"Morita","year":"2004","journal-title":"J Pain Symptom Manage"},{"key":"2024051713081435000_13.e3.e1191.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.10.018"},{"key":"2024051713081435000_13.e3.e1191.20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2020.1052","article-title":"Olanzapine for the treatment of advanced cancer-related chronic nausea and\/or vomiting: a randomized pilot trial","volume":"6","author":"Navari","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024051713081435000_13.e3.e1191.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3371-3"},{"key":"2024051713081435000_13.e3.e1191.22","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00520-018-4593-3","article-title":"Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study","volume":"27","author":"Harder","year":"2019","journal-title":"Support Care Cancer"},{"key":"2024051713081435000_13.e3.e1191.23","doi-asserted-by":"publisher","DOI":"10.1191\/0269216305pm972oa"},{"key":"2024051713081435000_13.e3.e1191.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4404-8","article-title":"A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment","volume":"18","author":"Hardy","year":"2018","journal-title":"BMC Cancer"},{"key":"2024051713081435000_13.e3.e1191.25","doi-asserted-by":"publisher","DOI":"10.1191\/026921601678576239"},{"key":"2024051713081435000_13.e3.e1191.26","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jpainsymman.2019.05.004","article-title":"Harms from haloperidol for symptom management in palliative care-a post hoc pooled analysis of three randomized controlled studies and two consecutive cohort studies","volume":"58","author":"Matsuoka","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"2024051713081435000_13.e3.e1191.27","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"2024051713081435000_13.e3.e1191.28","doi-asserted-by":"publisher","DOI":"10.1186\/1472-684X-4-7"},{"key":"2024051713081435000_13.e3.e1191.29","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2022-003795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:38:54Z","timestamp":1715985534000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2022-003795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":29,"journal-issue":{"issue":"e3","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/spcare-2022-003795"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2022-003795","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]}}}